aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
aTyr Pharma, Inc.NASDAQ: ATYR
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$138K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$215K. Over 3 fiscal years it compounded at -63.9% a year.
Context
- Capital expenditures amounted to 40.5% of revenue in FY2025, up 12.9 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near -$138K or moves back toward the trailing-twelve-month quarterly average of -$53.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (77K) USD
- Year-over-year change
- -18.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77K) | -18.5% |
| FY2024 | 2024-12-31 | (65K) | +98.5% |
| FY2023 | 2023-12-31 | (4.22M) | -156.9% |
| FY2022 | 2022-12-31 | (1.64M) | -754.7% |
| FY2021 | 2021-12-31 | (192K) | — |
Capital Expenditures vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +347.9% is the highest of 7, against a peer median of -48.1%.
- Capital expenditures amounts to 113.2% of revenue for ATYR, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.63M USD | -19.2% | -8.3% | — |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$745.58K CAD | -52.4% | -14.0% | 4.1% |
| LTM Mar 2026 | $215K USD | +347.9% | -63.9% | 113.2% | |
| LTM Mar 2026 | $202K USD | -43.7% | -47.0% | — | |
| LTM Mar 2026 | $54K USD | -89.3% | -70.5% | 0.1% | |
| LTM Mar 2026 | $16K USD | -80.5% | +128.9% | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| Peer median (excluding ATYR) | — | -48.1% | -14.0% | 0.1% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.61M | 2.15M | 2.6M | 2.99M | 5M |
| Change in Working Capital | (2.59M) | (833K) | 15.01M | (6.92M) | 7.45M |
| Accounts Receivables | 1.6M | (11.92M) | 9.05M | 402K | 863K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 47K | 0 | 3.26M | (1.34M) | (33K) |
| Other Working Capital | (4.24M) | 11.09M | 2.7M | (5.98M) | 6.62M |
| Other Non-Cash Items | 363K | 441K | (3.19M) | (2.71M) | (1.87M) |
| Operating Cash Flow | (33.08M) | (41.89M) | (33.22M) | (69.12M) | (61.99M) |
| Capital Expenditures | (192K) | (1.64M) | (4.22M) | (65K) | (77K) |
| Acquisitions (Net) | 50K | 0 | 0 | 7K | 12K |
| Purchases of Investments | (126.51M) | (42.12M) | (106.98M) | (69.1M) | (93.45M) |
| Sales of Investments | 35.08M | 90.83M | 91.05M | 86.39M | 86.6M |
| Other Investing Activities | 0 | 179K | 15K | 0 | 1.85M |
| Investing Cash Flow | (91.57M) | 47.25M | (20.13M) | 17.23M | (5.05M) |
| Debt Repayment | 0 | (66K) | (394K) | (497K) | (539K) |
| Common Stock Issued | 109.95M | 5.47M | 66.52M | 40.26M | 66.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 73K | 45K | 105K | 100K | 0 |
| Financing Cash Flow | 110.03M | 5.45M | 66.23M | 39.86M | 66.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (14.62M) | 10.81M | 12.88M | (12.02M) | (1.03M) |
| Free Cash Flow | (33.27M) | (43.53M) | (37.44M) | (69.18M) | (62.06M) |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.